Novel approaches to the stratified management of knee osteoarthritis分层管理膝关节骨关节炎的新方法Nature Reviews RheumatologyIF32.72025-10-030PRE
The European Innovation Network as a hub for medicines innovation in EuropeNATURE REVIEWS DRUG DISCOVERYIF101.82024-03-110PRE
An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilanceDRUG SAFETYIF3.82023-09-147PRE
The changing landscape of treatment options in childhood acute lymphoblastic leukaemiaDRUG DISCOVERY TODAYIF7.52022-05-013PRE
Improving the data quality of spontaneous ADR reports: a practical example from MaltaEXPERT OPINION ON DRUG SAFETYIF3.12021-10-224PRE
Aducanumab for Alzheimer's disease: A regulatory perspectivePHARMACOLOGICAL RESEARCHIF10.52021-09-0144OAAI
Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EUEXPERT OPINION ON DRUG SAFETYIF3.12021-04-225PREAI
Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human UseAAPS PHARMSCITECHIF42017-10-129OAAI
Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspectiveSAUDI PHARMACEUTICAL JOURNALIF3.42017-02-013OAAI
A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management systemEXPERT OPINION ON DRUG SAFETYIF3.12016-10-245PREAI
Comment On: EU's New Pharmacovigilance Legislation: Considerations for BiosimilarsDRUG SAFETYIF3.82013-12-131PREAI
Regulatory evaluation of Glybera in Europe - two committees, one missionNATURE REVIEWS DRUG DISCOVERYIF101.82013-08-1952OA
The New EU Legislation on Pharmacovigilance and Changing Models for Drug Development ReplyDRUG SAFETYIF3.82011-06-010PREAI
Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? A Review of the New EU Legislation on PharmacovigilanceDRUG SAFETYIF3.82011-03-0175PREAI